

GROWTH HORMONE

Tesamorelin

Stabilised GHRH Analogue

FDA-approved GHRH analogue for visceral fat reduction. Strong GH-pulse amplification.

| | | | |
|--|---------------------------------------|--|-------------------------------------|
| MECHANISM Stabilised GHRH analogue — enhanced pituitary GH pulse amplitude | DOSAGE 1–2 mg once daily SC | HALF-LIFE ~26 minutes (sustained GH elevation) | FORMAT Lyophilised powder |
|--|---------------------------------------|--|-------------------------------------|

| | | | | | |
|-----------------------------|----------------------|---------------------------|-----------------------------------|-----------------------------|-----------------------------|
| BATCH NU-TES-1573 | LOT 676573 | CAS 218949-48-5 | FORMULA C221H366N72O... | ISSUED 2025-07-04 | RETEST 2026-07-04 |
|-----------------------------|----------------------|---------------------------|-----------------------------------|-----------------------------|-----------------------------|

OVERVIEW

Tesamorelin is a stabilised GHRH analogue with greater potency and a longer half-life than native GHRH. It is the only GHRH-class peptide with FDA approval (Egrifta) — specifically for HIV-associated lipodystrophy, where it reduces visceral adipose tissue by ~15–18%.

MECHANISM OF ACTION

Stabilised GHRH analogue — enhanced pituitary GH pulse amplitude

KEY RESEARCH BENEFITS

- FDA-approved mechanism for visceral fat reduction
- Reduces trunk fat by 15–18% in clinical studies
- Stronger GH pulse amplitude than sermorelin
- Improves cognitive function in older adults
- Insulin-sensitising secondary effects

RESEARCH NOTES

Pivotal FDA trials (LIPO-010A/B, N = 816) showed significant visceral fat reduction and IGF-1 normalisation. Cognitive benefits reported in a separate MCI trial (NCT01699867).

STORAGE & STABILITY

Lyophilised: -20 °C, stable >=24 months. Reconstituted: 2–8 °C, use within 21 days.